Multiple sclerosis: disease-modifying therapies
You must score at least 70% in this module to pass. Ensure you have read ‘Multiple sclerosis: disease-modifying therapies’ before attempting to complete the module.
This module can be taken up to three times. Once you have passed, you can view the correct answers and download a certificate as a record of your learning.
Additional CPD modules are available in the ‘My CPD’ section of your account.
0 of 15 Questions completed
You have already completed the quiz before. Hence you can not start it again.
Quiz is loading…
You must sign in or sign up to start the quiz.
You must first complete the following:
0 of 15 Questions answered correctly
Time has elapsed
You have reached 0 of 0 point(s), (0)
Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)
What is the usual age of presentation of multiple sclerosis?CorrectIncorrect
What is the most common type of presentation in multiple sclerosis?CorrectIncorrect
How many disease modifying treatments are currently available for relapsing remitting multiple sclerosis (RRMS)?CorrectIncorrect
What is the predominant aim of treatment with disease modifying treatments in relapsing remitting multiple sclerosis (RRMS)?CorrectIncorrect
The main target for disease modifying treatments (DMTs) is T and B lymphocytes, though different mechanisms of action. Which of the following DMTs acts by altering the trafficking (movement) of lymphocytes by preventing their egress into the blood stream, retaining them in the lymph nodes?CorrectIncorrect
Who is the most appropriate person to diagnose multiple sclerosis and determine eligibility for disease modifying treatments?CorrectIncorrect
John Cunningham virus serology is measured to determine risk of progressive multifocal leukoencephalopathy for which disease modifying treatments?CorrectIncorrect
Which disease-modifying treatment requires a genetic test for CYP2C9 to determine their metaboliser status?CorrectIncorrect
Which screening tests are recommended prior to starting the first disease-modifying treatment?CorrectIncorrect
Flu-like symptoms for 24 hours after the dose is common with which of the following disease-modifying treatments?CorrectIncorrect
Which of the following disease-modifying treatments always requires cardiac monitoring with the first dose?CorrectIncorrect
How long should a patient be on disease-modifying treatment for before an assessment on efficacy can be made?CorrectIncorrect
Which of the following disease-modifying treatments can be used to treat primary progressive multiple sclerosis?CorrectIncorrect
Timing of disease-modifying treatment (DMT) initiation in relation to vaccines is important as live vaccines are contraindicated while immunosuppressed and inactivated vaccines may be less effective. If a live vaccine is required, when should it be given in relation to the first immunosuppressive DMT?CorrectIncorrect
Which of the following side effects are common with dimethyl fumarate and can be reduced by taking the tablets after meals high in fats or proteins?CorrectIncorrect